How Does Mavyret Work? Mechanism of Action Explained in Plain English

Mavyret (glecaprevir/pibrentasvir) is a combination drug: it contains two separate antiviral medications that each attack a different part of the hepatitis C virus's life cycle. By blocking the virus in two places at once, Mavyret makes it nearly impossible for the virus to survive, replicate, or develop resistance. Here's how it works—no medical degree required.

First: Understanding the Hepatitis C Virus

The hepatitis C virus (HCV) is an RNA virus that primarily infects liver cells. Once it gets inside a liver cell, it hijacks the cell's machinery to make copies of itself. The more copies it makes, the more liver cells get infected, and over time, this leads to liver inflammation, scarring (fibrosis), and eventually cirrhosis or liver cancer if untreated.

To replicate, the virus depends on specific proteins—enzymes and structural components—that your normal cells don't have. This makes HCV proteins ideal drug targets: blocking them stops the virus without harming your own cells.

How Glecaprevir Works (NS3/4A Protease Inhibitor)

Glecaprevir targets a protein called NS3/4A protease—a molecular "scissors" that the hepatitis C virus uses to cut a large viral precursor protein into the specific pieces it needs to function.

Think of it like this: the hepatitis C virus manufactures all its parts in a single long chain, like a string of Lego pieces still attached. The NS3/4A protease is the tool that snips that chain into individual, usable parts. Without it, the virus can produce parts but can't assemble working copies of itself.

Glecaprevir fits into the active site of the NS3/4A protease and blocks it—like sticking chewing gum into a lock. The protease can no longer snip the viral chain. No snipping means no functional viral pieces. No functional viral pieces means no new virus.

How Pibrentasvir Works (NS5A Inhibitor)

Pibrentasvir targets a different viral protein: NS5A. This protein has two main jobs for the hepatitis C virus: it helps copy the viral RNA (the genetic blueprint for making new viruses), and it helps assemble new virus particles so they can exit the liver cell and infect more cells.

NS5A is like the virus's project manager—it coordinates RNA copying (replication) and also supervises the packaging of new viral copies into particles that bud out of the cell. Pibrentasvir binds to NS5A and disrupts both functions: it scrambles replication AND assembly at the same time.

This dual action within a single inhibitor is part of why pibrentasvir is a second-generation NS5A inhibitor with potency against HCV variants that were resistant to older NS5A inhibitors like ledipasvir (found in Harvoni).

Why the Combination Works Better Than Either Drug Alone

HCV mutates rapidly—much faster than the flu virus. If you use only one antiviral drug, the virus can develop a resistance mutation that makes it immune to that drug while still surviving in enough copies to keep replicating. By using two drugs with completely different targets, Mavyret dramatically reduces the chance of resistance.

For the virus to escape Mavyret, it would need to simultaneously develop two different resistance mutations—one against glecaprevir AND one against pibrentasvir. The probability of this happening is extremely low, which is why cure rates reach 96–98%.

Why Is Mavyret Pangenotypic?

HCV has 6 major genotypes (numbered 1–6) that differ somewhat in their genetic sequence. Older hepatitis C drugs were genotype-specific—they only worked against certain variants. Mavyret is "pangenotypic" because both glecaprevir and pibrentasvir were designed to bind to HCV proteins in regions that are highly conserved across all genotypes. That means these proteins look almost identical in genotypes 1, 2, 3, 4, 5, and 6—and both drugs fit all of them.

This makes Mavyret simpler to prescribe—doctors don't have to wait for genotype testing before starting treatment, and patients with rare genotypes (4, 5, or 6) have the same access to an 8-week cure as those with common genotype 1.

What Happens to Your Body After Mavyret Works?

Within the first few weeks of taking Mavyret, your HCV viral load (the amount of virus in your blood) typically drops dramatically. By the end of treatment, most patients have undetectable viral levels. Your immune system then clears the remaining viral particles and infected cells.

After treatment ends, your doctor will check an HCV RNA test at 12 weeks post-treatment. If it's negative (undetectable), you're considered cured. Your liver will begin to heal—in many patients, liver fibrosis can partially or fully reverse after HCV clearance, especially in those who were treated early.

Want to learn more? See our full overview: what is Mavyret and how is it taken. And if you want to know what to expect physically during treatment, read about Mavyret side effects and when to call your doctor.